Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations
NCT01911871 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110
Last updated 2026-02-05
Summary
The investigators' primary objective is to study prevalences of myocardial iron overload, defined as a cardiac T2\*\< 20 ms, in 3 populations of multiply transfused patients, affected with thalassemia, sickle cell disease, and myelodysplasia.
Conditions
- Thalassemia
- Sickle Cell Disease
- Myelodysplasia
Interventions
- BIOLOGICAL
-
Blood sample
a blood sample was taken on the day of inclusion
Sponsors & Collaborators
- collaborator INDUSTRY
-
URC-CIC Paris Descartes Necker Cochin
collaborator OTHER -
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Mariane de montalembert, MD/PhD · Groupement Hospitalier Necker
Eligibility
- Min Age
- 6 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-03-31
- Primary Completion
- 2014-10-31
- Completion
- 2015-03-31
Countries
- France
Study Locations
More Related Trials
-
Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
NCT00564941 ·Status: COMPLETED ·Phase: PHASE4
-
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
NCT01250951 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
NCT00000595 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia
NCT01709838 ·Status: COMPLETED ·Phase: PHASE4
-
Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency
NCT03079518 ·Status: COMPLETED ·Phase: PHASE2
-
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512226 ·Status: COMPLETED ·Phase: NA
-
Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses
NCT01948817 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
NCT00171821 ·Status: COMPLETED ·Phase: PHASE3
-
Multi-Center Study of Iron Overload: Survey Study (MCSIO)
NCT01913548 ·Status: COMPLETED
-
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512564 ·Status: COMPLETED
-
Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
NCT00800761 ·Status: COMPLETED ·Phase: PHASE4
-
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
NCT00560820 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
NCT00061763 ·Status: COMPLETED ·Phase: PHASE2
-
Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
NCT00103753 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
NCT01254227 ·Status: COMPLETED ·Phase: PHASE2
-
High-Tc Susceptometer to Monitor Transfusional Iron Overload
NCT01241357 ·Status: COMPLETED
-
Exploration of the Parameters Influencing the Effort Limitation of Patients Suffering From Homozygous Sickle Cell Anemia
NCT06743139 ·Status: COMPLETED
-
Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
NCT00873041 ·Status: COMPLETED ·Phase: PHASE2
-
An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
NCT02173951 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy
NCT01874405 ·Status: COMPLETED
-
Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity
NCT02619955 ·Status: COMPLETED
-
Multi-Center Study of Iron Overload: Pilot Study
NCT01114776 ·Status: COMPLETED
-
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
NCT00349453 ·Status: COMPLETED ·Phase: PHASE2
-
IRONHEART: Intravenous Iron in Non-ischaemic Heart Failure
NCT06542822 ·Status: RECRUITING
-
"Iron Overload and Endocrinological Diseases"
NCT06137079 ·Status: RECRUITING